Duchenne Muscular Dystrophy Market to Surpass USD 11.7 Bn by 2033, with Enhanced Diagnosis | Marketresearch.biz Report
January 24, 2024 01:26 ET
|
MarketResearch.biz
New York, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Duchenne muscular dystrophy market was valued at USD 3.5 billion in 2023 with significant growth and is projected to reach USD 11.7 billion by 2033 with...
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
December 05, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most...
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
December 04, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted...
FDA approves muscular dystrophy drug built on Children’s National research
October 27, 2023 09:27 ET
|
Children's National Hospital
WASHINGTON, D.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Boys with Duchenne muscular dystrophy (DMD) have a clinically proven, new treatment option with the Food and Drug Administration’s approval...
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
October 26, 2023 15:19 ET
|
Catalyst Pharmaceuticals, Inc.
AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for...
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
October 16, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that...
Duchenne Muscular Dystrophy Market to Propel at a Significant CAGR by 2032, Assesses DelveInsight | Key Companies - Pfizer, Santhera, Taiho, FibroGen, Sarepta, Capricor, Daiichi Sankyo, Solid Biosciences
September 27, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Duchenne Muscular Dystrophy Market to Propel at a Significant CAGR by 2032, Assesses DelveInsight | Key Companies - Pfizer, Santhera, Taiho,...
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023 16:17 ET
|
Catalyst Pharmaceuticals, Inc.
Achieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOYAchieved 2023 Second Quarter GAAP EPS Diluted of...
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
July 24, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
May 30, 2023 05:00 ET
|
AKAMPION
FDA grants orphan drug designation for MetrioPharm’s lead compound MP1032 for the treatment of Duchenne muscular dystrophy (DMD)DMD is a designated orphan disease in both Europe and the...